September 2026
a bipartisan house bill just proposed capping insulin at $35 per month
On September 3rd, a bipartisan group of House members introduced the INSULIN Act of 2026 — a bill that would cap out-of-pocket insulin costs at $35 per month for people with commercial insurance. The American Diabetes Association issued a formal statement in support the same day. (Source: [ADA press release](https://diabetes.org/newsroom/press-releases/american-diabetes-associations-statement-introduction-insulin-act-2026-0)) This is not the first time Congress has reached for this particular lever. The Inflation Reduction Act of 2022 capped insulin at $35/month for Medicare beneficiaries. The INSULIN Act extends that logic to private insurance — which covers the majority of Americans with diabetes who are not yet on Medicare. Before getting into the politics, it helps to remember what insulin actually is. Not a pharmaceutical product line. Not a brand. A peptide. A 51-amino-acid chain your body either makes or doesn't. A molecule first isolated in 1921 and first sold commercially in 1923. The legislation being debated in 2026 is about the economics of that molecule — not its biology.
The actual biology
insulin is a 51-amino acid peptide that tells cells when to take up glucose
Insulin is a peptide hormone synthesized by beta cells in the islets of Langerhans — clusters of specialized cells in the pancreas. The mature human insulin molecule consists of two chains (A chain: 21 amino acids; B chain: 30 amino acids) linked by disulfide bonds, for a total of 51 amino acids. Its primary signaling role is glucose homeostasis: when blood glucose rises, insulin is released, binds to the insulin receptor on target cells, and triggers a cascade that moves GLUT4 transporters to the cell surface, allowing glucose uptake. (Source: [PubMed insulin literature](https://pubmed.ncbi.nlm.nih.gov/?term=insulin+mechanism+peptide)) For people with type 1 diabetes, whose immune systems have destroyed the beta cells that produce insulin, exogenous insulin replacement is not optional — it is the difference between life and death. For type 2 diabetes, where cells become resistant to insulin's signal and beta cell function may decline over time, supplemental insulin is often necessary as the condition progresses. The molecule is among the most conserved in vertebrate evolution. Human and porcine insulin differ by a single amino acid — a structural stability that reflects roughly 500 million years of functional optimization.
The complicated part
the affordability battle is not about mechanism — it's about access
The INSULIN Act does not change insulin's molecular structure. It doesn't alter its mechanism, its dosing, or its efficacy. What it proposes to change is the maximum amount a person pays per month to access it. U.S. insulin prices are an outlier by every international comparison. A vial that costs manufacturers roughly $10 to produce can list for $300 or more at U.S. retail — a markup sustained not by the base molecule (off-patent since the 1980s) but by patent portfolios around delivery devices, formulation tweaks, and a pricing ecosystem involving manufacturers, pharmacy benefit managers, and insurers, each capturing margin before the product reaches the patient. The downstream effects are documented: rationing, emergency room visits, preventable complications, and a documented pattern of Americans crossing into Canada or Mexico to purchase insulin at prices that are typically one-fifth to one-tenth of domestic retail. These are not anecdotes — they are published findings in peer-reviewed journals.
What the data says
a century of clinical evidence and official labeling are the definition of the approved tier
The FDA approved commercial insulin in 1923, making it one of the longest-running approved drugs in U.S. history. The current labeling covers multiple formulations — rapid-acting, short-acting, intermediate-acting, long-acting, and premixed combinations — each FDA-reviewed and categorized in the National Library of Medicine's DailyMed database. (Source: [DailyMed insulin listings](https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=insulin)) The clinical trial record for insulin spans a century. A search of ClinicalTrials.gov returns thousands of registered studies covering glycemic control, pump therapy, closed-loop systems, hypoglycemia risk, and diabetes complications — a body of evidence no other peptide in this catalog approaches. (Source: [ClinicalTrials.gov insulin trials](https://clinicaltrials.gov/search?term=insulin+type+1+diabetes)) The evidence tier assignment for insulin is Approved. That classification carries a specific meaning at PeptideFactCheck: regulatory approval exists for at least one specific use, and the evidence base for those labeled uses is not in reasonable scientific dispute. What remains disputed — often loudly, online and in Congress — is not whether insulin works but whether the price at which it is sold in the United States is defensible. On that question, the clinical evidence is silent. Policy debates do not have PubMed IDs.
Approved — PeptideFactCheck stance
the science is as settled as it gets — the $35 question is about something else entirely
Insulin is not a biohacker peptide. It is not a nootropic, a recovery aid, or a longevity compound. It is a life-sustaining hormone that roughly 8 million Americans inject daily to survive. Its biology is not in question. The INSULIN Act of 2026 may or may not pass. Bipartisan support in the House doesn't guarantee Senate votes, conference reconciliation, or presidential signature. The ADA's endorsement is meaningful signal but not predictive. Similar proposals have stalled before. (Source: [ADA statement on the INSULIN Act](https://diabetes.org/newsroom/press-releases/american-diabetes-associations-statement-introduction-insulin-act-2026-0)) What PeptideFactCheck can offer here is the scientific layer: insulin is real, its mechanism is settled, its century of clinical data is public, and its evidence tier is as high as anything in medicine gets. The cost question is a separate domain — one where patient advocacy organizations, health economists, and legislators are the relevant authorities, not us. Follow the source trail. Read the ADA statement. Read the bill text when it posts. Source trail before certainty.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.